What is the total size of Alan Ezekowitz’s Fulcrum Therapeutics (FULC) share sale?

The Form 4 reports that Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics common stock. Using the weighted average price of $3.6452 per share, this represents an aggregate transaction value of roughly $65,600 based on the filing’s disclosed figures.

Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock. He sold 18,000 shares of Fulcrum Therapeutics, Inc. at a weighted average price of $3.6452 per share, executed as multiple trades within a disclosed price range.

The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Following this sale, Ezekowitz directly holds 10,927 shares of Fulcrum Therapeutics common stock.

Insider Trade Summary

Net Seller: 18,000 shares ($65,614)

Net Sell 1 txn

Insider Ezekowitz Alan

Role null

Sold 18,000 shs ($66K)

Type	Security	Shares	Price	Value
Sale	Common Stock	18,000	$3.6452	$66K

Holdings After Transaction: Common Stock — 10,927 shares (Direct, null)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Key Figures

Shares sold: 18,000 shares Weighted average sale price: $3.6452 per share Aggregate sale value (approx.): $65,600 +3 more

6 metrics

Shares sold 18,000 shares Common Stock sold on June 26, 2026

Weighted average sale price $3.6452 per share Open-market sale of Fulcrum Therapeutics common stock

Aggregate sale value (approx.) $65,600 18,000 shares at $3.6452 weighted average price

Shares owned after transaction 10,927 shares Direct holdings following June 26, 2026 sale

Net buy/sell shares -18,000 shares Form 4 transaction summary shows net-sell direction

Sale price range $3.555–$3.82 per share Multiple transactions within this range, forming weighted average

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1 trading plan financial

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale","transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock","transaction_date": "2026-06-26T00:00:00.000Z""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:30 PM Accepted by SEC EDGAR 06/30/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ezekowitz Alan

(Last)

(First)

(Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/26/2026		S⁽¹⁾		18,000	D	$3.6452⁽²⁾	10,927	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

	/s/ Greg Tourangeau, as attorney-in-fact for Alan Ezekowitz	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) disclose for Alan Ezekowitz?

Fulcrum Therapeutics disclosed that director Alan Ezekowitz sold 18,000 shares of common stock. The Form 4 shows an open-market sale at a weighted average price of $3.6452 per share, leaving him with 10,927 shares held directly after the transaction.

At what price did Alan Ezekowitz sell Fulcrum Therapeutics (FULC) shares?

The reported weighted average sale price was $3.6452 per Fulcrum Therapeutics share. Footnotes state the 18,000 shares were sold in multiple transactions at prices ranging from $3.555 to $3.82 per share, resulting in the disclosed weighted average figure.

How many Fulcrum Therapeutics (FULC) shares does Alan Ezekowitz hold after this Form 4 sale?

After the reported sale, Alan Ezekowitz directly owns 10,927 Fulcrum Therapeutics shares. Before the open-market transaction, his direct holdings were higher, and the filing shows this updated post-transaction position as the current direct ownership level.

Was the Fulcrum Therapeutics (FULC) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the sales were effected under a Rule 10b5-1 trading plan. The trading plan was adopted by the reporting person on March 27, 2026, indicating the transactions were pre-arranged rather than discretionary same-day trading decisions.

What does the price range disclosure mean in the Fulcrum Therapeutics (FULC) Form 4?

The filing notes that the reported sale price is a weighted average over multiple trades. Shares were sold between $3.555 and $3.82 per share, and the insider offers to provide detailed trade-by-trade pricing information to the company, security holders, or SEC staff on request.